Tag: lawsuits
-
Philips Breathing Devices Recall Update: FDA Releases Explosive New Findings in November 2021
What Philips Knew and When, What Philips Did or Did Not Do, Much More, From the FDA Form 483 Inspection Report (Posted by Tom Lamb at Drug Injury Watch) We occasionally go "off-topic" on this…
-
Xeljanz Risks of Cardiovascular Events, as Well as Cancers, Cause More Xeljanz Use Limitations
October 2021 UK’s MHRA Xeljanz Action Follows September 2021 FDA Xeljanz Drug Safety Communication Update (Posted by Tom Lamb at Drug Injury Watch) On September 1, 2021, we posted this article, “Xeljanz: FDA Warnings Updated:…
-
Possible Beovu Side Effects Discussed At American Society of Retina Specialists Annual Meeting In July 2020
Current Findings On Risks Of Occlusive Vasculitis And Vision Loss Following Beovu Injections For Treatment Of Wet AMD (Posted by Tom Lamb at DrugInjuryWatch.com) According to news reports, Beovu safety issues were…
-
June 2019 Actemra Label Change Adds Warnings About Increased Risks Of Liver Injury After Months Or Years Of Use
Serious Cases Of Hepatic Injury Some Of Which Have Resulted In Liver Transplant Or Death Reported As Side Effects (Posted by Tom Lamb at DrugInjuryWatch.com) On May 21, 2019 we posted this…
-
Amputations Side Effects: Invokana Only, Or Jardiance, Farxiga, And Other SGLT2 Inhibitors Diabetes Drugs, Too?
Increasing Degree Of Acknowledgement In Medical Literature That Toe, Foot, And Leg Amputations Are Drug-Class Side Effects (Posted by Tom Lamb at DrugInjuryWatch.com) We have been following developments in the medical realm…
-
Some Newer Diabetes Drugs Linked To Lower Limb Amputations: “Significantly Increased Risk”
New Study Suggests Possible Drug Class Side Effects Of SGLT-2 Inhibitors Such As Invokana, Jardiance, And Farxiga (Posted by Tom Lamb at DrugInjuryWatch.com) Sodium-glucose cotransporter 2 inhibitors (SGLT-2 inhibitors) are relatively new…
-
Bayer: Essure Permanent Birth Control Device Removal From US Market Is “Business Decision”
Or Is This Really An Essure Recall Due To High Numbers Of Adverse Events Reported To FDA And Related Essure Lawsuits (Posted by Tom Lamb at DrugInjuryWatch.com) We have reported developments concerning…
-
Rexulti Warnings For Compulsive Behavior And Impulse Control Problems Added To Drug Label
FDA: Patients Using Rexulti At Risk For Experiencing Intense Urges For Gambling And Inability To Control Conduct (Posted by Tom Lamb at DrugInjuryWatch.com) Rexulti® (brexpiprazole) was initially approved by the FDA in…